Blein Sophie, Barjhoux Laure, Damiola Francesca, Dondon Marie-Gabrielle, Eon-Marchais Séverine, Marcou Morgane, Caron Olivier, Lortholary Alain, Buecher Bruno, Vennin Philippe, Berthet Pascaline, Noguès Catherine, Lasset Christine, Gauthier-Villars Marion, Mazoyer Sylvie, Stoppa-Lyonnet Dominique, Andrieu Nadine, Thomas Gilles, Sinilnikova Olga M, Cox David G
INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Inserm, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France.
PLoS One. 2015 Sep 25;10(9):e0136192. doi: 10.1371/journal.pone.0136192. eCollection 2015.
Breast Cancer is a complex multifactorial disease for which high-penetrance mutations have been identified. Approaches used to date have identified genomic features explaining about 50% of breast cancer heritability. A number of low- to medium penetrance alleles (per-allele odds ratio < 1.5 and 4.0, respectively) have been identified, suggesting that the remaining heritability is likely to be explained by the cumulative effect of such alleles and/or by rare high-penetrance alleles. Relatively few studies have specifically explored the mitochondrial genome for variants potentially implicated in breast cancer risk. For these reasons, we propose an exploration of the variability of the mitochondrial genome in individuals diagnosed with breast cancer, having a positive breast cancer family history but testing negative for BRCA1/2 pathogenic mutations. We sequenced the mitochondrial genome of 436 index breast cancer cases from the GENESIS study. As expected, no pathogenic genomic pattern common to the 436 women included in our study was observed. The mitochondrial genes MT-ATP6 and MT-CYB were observed to carry the highest number of variants in the study. The proteins encoded by these genes are involved in the structure of the mitochondrial respiration chain, and variants in these genes may impact reactive oxygen species production contributing to carcinogenesis. More functional and epidemiological studies are needed to further investigate to what extent variants identified may influence familial breast cancer risk.
乳腺癌是一种复杂的多因素疾病,已鉴定出高外显率突变。迄今为止所采用的方法已确定了约占乳腺癌遗传度50%的基因组特征。已鉴定出一些低至中等外显率等位基因(每个等位基因的优势比分别<1.5和4.0),这表明其余的遗传度可能由这些等位基因的累积效应和/或罕见的高外显率等位基因来解释。相对较少的研究专门探索线粒体基因组中可能与乳腺癌风险相关的变异。基于这些原因,我们建议对诊断为乳腺癌、有乳腺癌家族史但BRCA1/2致病突变检测呈阴性的个体的线粒体基因组变异性进行探索。我们对GENESIS研究中的436例乳腺癌先证者的线粒体基因组进行了测序。正如预期的那样,在我们研究纳入的436名女性中未观察到共同的致病基因组模式。在该研究中观察到线粒体基因MT-ATP6和MT-CYB携带的变异数量最多。这些基因编码的蛋白质参与线粒体呼吸链的结构,这些基因中的变异可能影响活性氧的产生,从而促进致癌作用。需要更多的功能和流行病学研究来进一步调查所鉴定的变异在多大程度上可能影响家族性乳腺癌风险。